CDA | Evidence Driven
CDA | Evidence Driven

Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HD0007-000

Nirmatrelvir and ritonavir are oral medications given in combination to treat Covid-19. Specifically, these medications are used to treat mild to moderate COVID-19 in patients with confirmed SARS-CoV-2 infection who are at high risk for progression to severe COVID-19. Canada's Drug Agency conducted a review of the evidence and convened an Implementation Advice Panel to provide guidance regarding the optimal use of these medications.

Files

Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19 View PDF
Last Updated : January 28, 2022